Allo CAR T Myeloma Therapies with Jesus Berdeja, MD, Sarah Cannon Research Institute image

Allo CAR T Myeloma Therapies with Jesus Berdeja, MD, Sarah Cannon Research Institute

Posted on: Jun 27, 2022
Play Episode
Also available on
Description

TO JOIN THE SHOW BY PHONE, PLEASE CALL (347) 637-2631

CAR T therapies are expanding as multiple myeloma treatment options. In addition to the two currently FDA approved CAR T therapies (Abecma and Carvykti) which use a patient's own T cells in a production process, new allo (off-the-shelf) options are being developed in clinical trials. Dr. Jesus Berdeja is one of the leading CAR T experts in multiple myeloma and in this episode, he will share the current development taking place for allo CAR T therapies. Join us to learn more about this exciting field in myeloma research which may provide faster and more available treatment options for patients. 

Thanks to our episode sponsor

User uploaded media

Note: Myeloma Crowd Radio is becoming HealthTree Podcast for Multiple Myeloma

Overview

Jesus Berdeja, MD
Sarah Cannon Research Institute
Interview Date: June 27, 2022

CAR T therapy is both FDA approved and continues to be in development in clininical trials. While the Abecma and CARVYKTI products used commercially are autologous (meaning they use a patients' own T cells), a whole new set of CAR T products in developmnet are allogeneic, or "off-the-shelf." These allogeneic CAR T options could provide faster access, less bridging therapy and better availability. Learn more from CAR T myeloma expert Jesus Berdeja, MD about this class of new myeloma treatments in this important show.

Thanks to our episode sponsor

User uploaded media

 

On this episode
Healthtree contact Dr. Jesus Berdeja

Dr. Jesus Berdeja

Jesus G. Berdeja received his undergraduate degree from Stanford University and medical degree from Harvard University. He completed his internship and residency in the Department of Internal Medicine at the University of California in San Francisco and fellowships in medical oncology and hematology at Johns Hopkins University School of Medicine in Baltimore. Prior to joining the staff at the Sarah Cannon Research Institute and Tennessee Oncology, Dr. Berdeja held appointments in the Stem Cell and Bone Marrow Transplant Program and the Division of Hematology and Oncology at Loma Linda University in Loma Linda, California. Dr. Berdeja has been certified a Diplomate in internal medicine, medical oncology, and hematology by the American Board of Internal Medicine. Additionally, he is an active member of several professional organizations, including the International Myeloma Society, the American Society of Clinical Oncology, the American Society of Hematology, the International Myeloma Working Group, the Clinical Trials Myeloma Intergroup Committee, and the Center for International Blood and Marrow Transplant Research Plasma Cell Working Group. An active researcher, Dr. Berdeja has been the principal investigator on a number of funded clinical trials in the field of multiple myeloma. He has published extensively in the peer-reviewed literature and is a frequent invited lecturer.
Healthtree contact Jennifer Ahlstrom

Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.
Transcript

Related Content